EUVIMEDSkopri EUVIMED
Open access

Impacts of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation

W C Ian Janes, Mitchell G Fagan, J Matthew Andrews, David R Harvey, Geoff M Warden, Paul H Johnston, Michael K Organ

Canadian Urological Association Journal · 2023-12-21 · 18 (4)

DOI: 10.5489/cuaj.8519 ↗

At a glance

Journal article in Canadian Urological Association Journal, published online on 2023-12-21. Written by W C Ian Janes and 6 co-authors. Institution: Faculty of Medicine, Memorial University, St. John's, NL, Canada. Cited 7 times so far (Crossref). The full text is freely available in PubMed Central.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Renal cell carcinoma (RCC) is often associated with significant morbidity and mortality, with overall survival contingent on multiple factors — most importantly, disease stage at diagnosis. Disruptions in healthcare delivery during the COVID-19 pandemic have resulted in various reported diagnostic and treatment delays, which have had detrimental impacts on malignancies such as RCC.

Methods

Surgically managed cases of RCC at our center were identified using a retrospective chart review of all nephrectomies conducted from March 1, 2018, to February 28, 2023. Examination of disease characteristics in three time period cohorts (before, during, and following the COVID-19 pandemic) was undertaken. Timeframes were consistent with implementation and abolition of public health restrictions in the province of Newfoundland and Labrador.

Results

A total of 483 surgically managed RCC cases were identified during the study period. The median age was 65 years (interquartile range [IQR] 56–71), and 62.3% of patients were male. Demographics did not vary across timeframes. Before and during the pandemic, pathologic stage 3 (pT3) disease was reported in 38.9% and 35.4% of cases, respectively, whereas the post-pandemic period saw this presentation in 50.0% of patients. Surgical wait times increased significantly across study timeframes (p=0.003).

Conclusions

The first year following the COVID-19 pandemic saw an 11.1% increase in patients presenting with pT3 RCC. These findings are suggestive of a clinically significant stage migration, which paired with prolonged wait times for surgery, provide critical consideration in the urgency of diagnostic and treatment decisions for RCC in the immediate future.

Authors and institutions

  • Faculty of Medicine, Memorial University, St. John's, NL, Canada.
  • Division of Urology, Memorial University, St. John's, NL, Canada.
  • Division of Anesthesia, Health Sciences Centre, St. John's, NL, Canada.

Cite

APA

Janes, W. C. I., Fagan, M. G., Andrews, J. M., Harvey, D. R., Warden, G. M., Johnston, P. H., & Organ, M. K. (2023). Impacts of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation. Canadian Urological Association Journal, 18(4). https://doi.org/10.5489/cuaj.8519

Vancouver

Janes WCI, Fagan MG, Andrews JM, Harvey DR, Warden GM, Johnston PH, et al. Impacts of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation. Canadian Urological Association Journal. 2023;18(4). doi:10.5489/cuaj.8519

BibTeX
@article{Janes2023,
  author = {Janes, W C Ian and Fagan, Mitchell G and Andrews, J Matthew and Harvey, David R and Warden, Geoff M and Johnston, Paul H and Organ, Michael K},
  title = {Impacts of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation},
  journal = {Canadian Urological Association Journal},
  year = {2023},
  volume = {18},
  number = {4},
  doi = {10.5489/cuaj.8519}
}
Start for free →